Global Gastric Cancer Market By Type (Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor, Others), Stages (Stage I, Stage II, Stage III, Stage IV, Others), Diagnosis (Endoscopy, Biopsy, Imaging Tests, Exploratory Surgery, Others), Treatment (Surgery, Radiation Therapy, Chemotherapy, Targeted Therapy, Palliative Care, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others), Country (U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa) Industry Trends and Forecast to 2027
Market Analysis and Insights: Global Gastric Cancer Market
Gastric cancer market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market is growing with the healthy CAGR in the above-mentioned research forecast period. Rising prevalence of cancer related disorders worldwide and emerging markets are the factors responsible for the growth of this market.
Growing cases of gastrointestinal reflux disease drives the gastric cancer market. Due to adoption of unhealthy lifestyle such as obesity & smoking, genetic modification/alteration in genes and family history with cancer also boost up the gastric cancer market growth. However, increased advancement in the treatment of cancer and rise in population with obesity & other gastric diseases worldwide will boost up the gastric cancer market. But, lack of patient’s awareness, late symptom of cancer due to the presence of obesity and stringent FDA guidelines for the drug approval of new drug may hamper the gastric cancer market.
Gastric cancer is the condition characterized by the abnormal growth of cancerous cells within the stomach lining. This type of cancer also called as gastric adenocarcinoma usually difficult to diagnose in the earlier stage until after it spreads to other parts of the body. In 2017, National Cancer Institute (NCI) estimated that there will be approximately 28,000 new cases of stomach cancer and 1.7% of new cancer cases of stomach cancer in the United States. Symptoms of gastric cancer include unexplained, persistent nausea, stomach pain, fatigue, feeling bloated after eating, persistent vomiting and unintentional weight loss.
This gastric cancer market report provides details of market share, new developments and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographical expansions and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.
Global Gastric Cancer Market Scope and Market Size
Gastric cancer market is segmented on the basis of type, stage, diagnosis, treatment, route of administration, end-users and distribution channel.
- On the basis of type, the gastric cancer market is segmented into adenocarcinoma, lymphoma, gastrointestinal stromal tumor, carcinoid tumor and others
- On the basis of stages, the gastric cancer market is segmented into stage I, stage II, stage III, stage IV and others
- On the basis of diagnosis, the gastric cancer market is segmented into endoscopy, biopsy, imaging tests, exploratory surgery and others
- On the basis of treatment, the gastric cancer market is segmented into surgery, radiation therapy, chemotherapy, targeted therapy, palliative care and others. Targeted treatment includes trastuzumab, ramucirumab, imatinib, sunitinib, regorafenib and other
- Route of administration segment of gastric cancer market is segmented into oral, parenteral and others.
- On the basis of end-users, the gastric cancer market is segmented into hospitals, specialty clinics and others
- On the basis of distribution channel, the gastric cancer market has also been segmented into hospital pharmacy, retail pharmacy, others
Key Development in the Market:
- In April 2014, Eli Lilly and Company received FDA approval for CYRAMZA (ramucirumab) for the advanced gastric or gastro-esophageal junction adenocarcinoma, as a single agent or in combination with paclitaxel, after prior fluoropyrimidine or platinum-containing chemotherapy. With this, the company has strengthened its brand image in the market.
Gastric Cancer Market Country Level Analysis
Gastric cancer market is analysed and market size information is provided by country, type, stages, diagnosis, treatment, route of administration, end-users and distribution channel as referenced above.
The countries covered in the gastric cancer market report are U.S., Canada, Mexico in North America, Brazil, Argentina, Peru, Rest of South America, as part of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, in Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa, as a part of Middle East and Africa.
North America accounts the largest market share due to the presence of key manufacture of the product, high research and development and healthcare expenditure and skilled professionals. Europe is considered to be second largest market for gastric cancer due to increased cancer chemotherapy & surgeries. Asia-Pacific is expected to account for the largest market share over coming years for the gastric cancer market due to increased government awareness programs and number of generic drugs.
The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Patient Epidemiology Analysis
Gastric cancer market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Competitive Landscape and Gastric Cancer Market Share Analysis
Gastric cancer market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to gastric cancer market.
The major players covered in the gastric cancer market are Genetech Inc., Pfizer Inc., Mylan N.V., Daiichi Sankyo Company Limited, Samsung Bioepis, Celltrion Inc., Amgen Inc., Novartis AG, Eli Lilly and Company, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Hikma Pharmaceutical PLC, and Bayer AG among others.
Customization Available: Global Gastric Cancer Market
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analysed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.